# PT-141 for Women: HSDD, Vyleesi & Research **By TelosRX Editorial Team** · 2026-08-14 **Women are the population bremelanotide was actually studied and approved for. PT-141 for women targets low sexual desire at its source in the brain, not blood flow. Here is what the trials found, and how [PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) works.** Low desire gets treated as a mood, a relationship issue, or something you should simply want more. For a specific group of women, it is none of those. It is a recognised clinical condition called hypoactive sexual desire disorder, or HSDD, and it is the one indication bremelanotide holds FDA approval for. ## What HSDD Actually Means HSDD is not simply having a lower sex drive than someone else. The definition is narrow on purpose, because the wording determines who the research applies to. The FDA-approved indication for Vyleesi covers **acquired, generalized HSDD in premenopausal women**. Each of those words is doing work: - **Acquired** means desire was there before and then declined. Lifelong low desire is different, and was not what the trials studied. - **Generalized** means it happens across situations and partners, not only in one relationship. Situational low desire points somewhere else. - **Distressing** means it bothers you. If low desire genuinely does not trouble you, it is not classified as a disorder. Wanting to want is part of the definition. - **Not otherwise explained** means the change is not attributable to another medical or psychiatric condition, relationship problems, or the effects of a medication or substance. That last point is the one most often skipped. Antidepressants, hormonal contraception, thyroid conditions, chronic pain and untreated depression all affect desire. A careful evaluation looks for those first, because if one is the driver, the answer is to address it rather than layer something on top. ## How Bremelanotide Works, Briefly PT-141 is the research name for bremelanotide. Same molecule, different label on the vial. It is a melanocortin receptor agonist acting at MC3R and MC4R receptors in the hypothalamus, in the brain circuitry associated with drive and motivation rather than in blood vessels. Because the action is central, it does not strictly require sexual stimulation to initiate a response, the opposite of how PDE5 inhibitors behave. We cover the receptor biology in [What Is PT-141? How Bremelanotide Works](https://www.telosrx.com/blogs/peptides/what-is-pt-141-bremelanotide-guide), and the contrast with oral erectile medications in [PT-141 vs Viagra and Cialis](https://www.telosrx.com/blogs/peptides/pt-141-vs-viagra-cialis). Bremelanotide shares a research lineage with tanning-related melanocortin compounds. It is not a tanning product and should never be described as one. ## What the RECONNECT Trials Measured The evidence base here is unusually solid for a peptide. RECONNECT was two identical phase 3 randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD, published in _Obstetrics and Gynecology_ in 2019. Participants used bremelanotide 1.75 mg subcutaneously as needed over 24 weeks. The [co-primary endpoints](https://pubmed.ncbi.nlm.nih.gov/31599840/) were change from baseline in the Female Sexual Function Index desire domain score and in the Female Sexual Distress Scale item measuring distress about low desire. Both endpoints were met with statistical significance against placebo. That two-part structure is the point: the FDA required evidence that a treatment moved **both desire and the distress attached to it**. A published [review of the RECONNECT data](https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/) covers the design and outcomes in detail. What the trials did not test matters too. They did not study postmenopausal women or lifelong low desire. Trial averages describe groups, not individuals. Some participants responded, some did not. If acquired, generalized, distressing low desire sounds like your experience, a licensed provider can review your history privately and tell you whether PT-141 is a reasonable option. [See PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) ## Vyleesi and Compounded PT-141 Are Not the Same Thing This distinction gets blurred online, so here it is directly. Vyleesi is the FDA-approved branded product. Compounded PT-141 is **not FDA-approved**. It is prepared by licensed US compounding pharmacies under federal compounding regulations, a different regulatory pathway.   Vyleesi Compounded PT-141 Active molecule Bremelanotide Bremelanotide FDA approval Approved 2019 for acquired, generalized HSDD in premenopausal women Not FDA-approved Regulatory basis New drug application Prepared by licensed US compounding pharmacies under federal compounding regulations Delivery 1.75 mg single-use subcutaneous autoinjector Subcutaneous, formulation may vary by state Label timing At least 45 minutes before anticipated sexual activity Determined by the prescribing provider Label frequency limits No more than one dose in 24 hours, no more than eight doses per month Determined by the prescribing provider Those label parameters describe what was studied and approved. They are published information, not instructions. What is appropriate for you is decided by the prescribing provider. Our [PT-141 dosage guide](https://www.telosrx.com/blogs/peptides/pt-141-dosage-guide) covers what the clinical research specifies. ## What Women Reported in the Trials Per the [Vyleesi prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf), nausea was the most common adverse reaction at roughly 40 percent, usually most pronounced after the first dose and generally transient. Flushing was reported by about 20 percent, injection site reactions by about 13 percent, and headache by about 11 percent. The label also documents transient increases in blood pressure with a modest decrease in heart rate, typically resolving within 12 hours. Focal hyperpigmentation, meaning darkened patches of skin, has been reported, and was more frequent with repeated daily dosing than with intermittent use. It does not always resolve after stopping. Our article on [PT-141 side effects and what trials reported](https://www.telosrx.com/blogs/peptides/pt-141-side-effects-safety) covers each of these. ## Who Is Not a Candidate Several come straight from the trial exclusion criteria and the approved label. 1. **Uncontrolled hypertension or known cardiovascular disease.** The trials excluded these participants and the label contraindicates use. 2. **Postmenopausal women.** The approval is specific to premenopausal women, so this falls outside what was studied. 3. **Lifelong rather than acquired low desire.** If desire was never present, the RECONNECT population does not describe you. 4. **Situational low desire.** If desire is intact in some contexts and absent in others, that pattern usually points to something other than HSDD. 5. **Low desire with an identifiable cause.** Medication effects, untreated depression, thyroid dysfunction, pain conditions and relationship distress each deserve their own attention first. 6. **Pregnancy, or trying to conceive.** Raise this with your provider first. None of these are moral judgments. They are the edges of what the evidence covers. ## Where This Sits in a Bigger Picture Desire is multifactorial, and no single intervention addresses all of it. Sleep, stress, hormonal shifts, medication changes and relationship context all pull on the same system. A treatment aimed at central desire pathways is one input among several. Men are a separate conversation, since bremelanotide use in men is off-label and rests on earlier-phase evidence. We cover that in [PT-141 for men](https://www.telosrx.com/blogs/peptides/pt-141-for-men-research-guide), and the broader mechanism research in [5 research-backed benefits of PT-141](https://www.telosrx.com/blogs/peptides/pt-141-bremelanotide-benefits-research-guide). Telos Rx offers compounded PT-141 as an as-needed subcutaneous dose taken ahead of anticipated intimacy, available in all 50 states, with formulations that may vary by state. Everything runs through a provider-reviewed, asynchronous online process, so there is no appointment to schedule. Treatment is subject to medical approval by a licensed provider, and approval is not guaranteed. ## Frequently Asked Questions ### Is PT-141 approved for women? Bremelanotide, sold as Vyleesi, received FDA approval in 2019 for acquired, generalized HSDD in premenopausal women. That is the only FDA-approved indication for the molecule. Compounded PT-141 contains the same active peptide but is not FDA-approved and is prepared by licensed US compounding pharmacies under federal compounding regulations. ### How do I know if I have HSDD or just low libido? HSDD is defined as low desire that was previously present, occurs across situations rather than in one context, causes you genuine distress, and is not explained by another medical condition, a relationship problem, or a medication. Occasional dips in libido are normal and are not the same thing. A licensed provider makes that assessment, not a quiz. ### How does PT-141 differ from medications for erectile dysfunction? PDE5 inhibitors act on blood vessels and require sexual stimulation to produce an effect. Bremelanotide acts centrally at melanocortin receptors in the hypothalamus, in the circuitry tied to desire itself. Because the mechanism is central rather than vascular, it does not strictly require stimulation to initiate a response. ### What did women in the RECONNECT trials report as side effects? Nausea was the most common at roughly 40 percent, typically strongest after the first dose and usually transient. Flushing, injection site reactions and headache were also reported. The label documents brief increases in blood pressure with a modest heart rate decrease, and focal skin darkening with repeated dosing. Discuss all of these with your provider. ### Can I use PT-141 after menopause? The FDA-approved indication covers premenopausal women only, because that is the population the RECONNECT trials enrolled. Postmenopausal use falls outside the approved indication and outside the phase 3 evidence. If low desire started around or after menopause, tell your provider, since the underlying drivers and the appropriate options may be different. ### How is PT-141 taken? Vyleesi is a 1.75 mg subcutaneous autoinjector, and its label specifies administration at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month. Compounded PT-141 is also subcutaneous and taken as needed. Your prescribing provider determines what applies to you. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ If low desire has been quietly wearing on you, you do not have to work it out alone. Read the full details on [PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141), or [start your private online visit for women](https://start.telosrx.com/start-online-visit/pt141women). Approval is not guaranteed. **Tags:** bremelanotide, HSDD, libido, peptides, PT-141, sexual health, Vyleesi, womens health --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/pt-141-for-women-hsdd-guide)